Phio Pharma Shares Are Moving Higher On INTASYL Preclinical Data At ESMO Presentation

• Phio Pharmaceuticals Corp (NASDAQ: PHIO) has announced preclinical results from a new study of a self-delivering RNAi (INTASYL) therapeutic platform.

• The data were presented at the European Society of Medical Oncology (ESMO) Congress 2021.

• The study was performed to show the synergistic activity of co-targeting PD-1 and BRD4 with one INTASYL formulation (PH-3861) in a preclinical in vivo hepatocellular carcinoma (liver cancer) model.

• The results show that up to 83% of the animals treated with PH-3861 had a complete response at low doses.

• The treatment induced a durable and specific systemic antitumor immune response without requiring further treatment.

• Related Link: Phio Pharma's PH-762 Shows Encouraging Antitumor Efficacy In Preclinical Studies.

• Price Action: PHIO stock is up 18.80% at $2.34 during the premarket session on the last check Thursday.

• Check out our coverage of the European Society for Medical Oncology Congress (ESMO21)

See more from Benzinga

• Click here for options trades from Benzinga

• Athenex Shares Are Trading Higher On Positive Oral Paclitaxel Data From Solid Tumor Trial

• Exelixis' Cabometyx Combo Trial Shows Benefit In Kidney Cancer Regardless Of Prior Surgery

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.